These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 34464974)

  • 1. Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse.
    Samra B; Khoury JD; Morita K; Ravandi F; Richard-Carpentier G; Short NJ; El Hussein S; Thompson P; Jain N; Kantarjian H; Jabbour E
    Blood Adv; 2021 Oct; 5(20):3913-3918. PubMed ID: 34464974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
    Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
    Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.
    Fayad L; Thomas D; Romaguera J
    Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 2():S57-62. PubMed ID: 18284717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
    Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
    Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of chemotherapy protocols for hematological malignancies: H-CVAD versus GELA/BURKIMAB/PETHEMA LAL.
    Marín-Sánchez A; Martínez-Fernández G; Gómez-Catalán I; Montoya-Morcillo MC; Algarra-Algarra JL; Ibañez-García Á; Hernández-Fernández F; Romero-Macías JR
    Exp Hematol; 2021 Sep; 101-102():49-57. PubMed ID: 34403757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.
    Cortes J; Thomas D; Rios A; Koller C; O'Brien S; Jeha S; Faderl S; Kantarjian H
    Cancer; 2002 Mar; 94(5):1492-9. PubMed ID: 11920506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study.
    Zayac AS; Evens AM; Danilov A; Smith SD; Jagadeesh D; Leslie LA; Wei C; Kim SH; Naik S; Sundaram S; Reddy N; Farooq U; Kenkre VP; Epperla N; Blum KA; Khan N; Singh D; Alderuccio JP; Godara A; Yazdy MS; Diefenbach C; Rabinovich E; Varma G; Karmali R; Shao Y; Trabolsi A; Burkart M; Martin P; Stettner S; Chauhan A; Choi YK; Straker-Edwards A; Klein A; Churnetski MC; Boughan KM; Berg S; Haverkos BM; Orellana-Noia VM; D'Angelo C; Bond DA; Maliske SM; Vaca R; Magarelli G; Sperling A; Gordon MJ; David KA; Savani M; Caimi P; Kamdar M; Lunning MA; Palmisiano N; Venugopal P; Portell CA; Bachanova V; Phillips T; Lossos IS; Olszewski AJ
    Haematologica; 2021 Jul; 106(7):1932-1942. PubMed ID: 33538152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
    Weiser MA; O'Brien S; Thomas DA; Pierce SA; Lam TP; Kantarjian HM
    Cancer; 2002 Jan; 94(2):285-91. PubMed ID: 11900213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
    Thomas DA; O'Brien S; Cortes J; Giles FJ; Faderl S; Verstovsek S; Ferrajoli A; Koller C; Beran M; Pierce S; Ha CS; Cabanillas F; Keating MJ; Kantarjian H
    Blood; 2004 Sep; 104(6):1624-30. PubMed ID: 15178574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
    Kantarjian HM; O'Brien S; Smith TL; Cortes J; Giles FJ; Beran M; Pierce S; Huh Y; Andreeff M; Koller C; Ha CS; Keating MJ; Murphy S; Freireich EJ
    J Clin Oncol; 2000 Feb; 18(3):547-61. PubMed ID: 10653870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of Hyper-CVAD/MA and CHALL-01 regimens in the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia patients under 60 years old].
    Huang AJ; Wang LB; Du J; Tang GS; Cheng H; Gong SL; Gao L; Qiu HY; Ni X; Chen J; Chen L; Zhang WP; Wang JM; Yang JM; Hu XX
    Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):625-632. PubMed ID: 31495127
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness of modified hyper-CVAD chemotherapy regimen in the treatment of adult acute lymphoblastic leukemia: a retrospective experience.
    Jalaeikhoo H; Rajaeinejad M; Keyhani M; Zokaasadi M; Dehghani Firoozabadi MM
    Cancer Med; 2018 Mar; 7(3):594-599. PubMed ID: 29383863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma.
    Ritchie DS; Seymour JF; Grigg AP; Roberts AW; Hoyt R; Thompson S; Szer J; Prince HM
    Ann Hematol; 2007 Feb; 86(2):101-5. PubMed ID: 17089127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma.
    Dabaja BS; Ha CS; Thomas DA; Wilder RB; Gopal R; Cortes J; Bueso-Ramos C; Hess MA; Cox JD; Kantarjian HM
    Cancer; 2002 May; 94(10):2738-44. PubMed ID: 12173345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
    Thomas DA; O'Brien S; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Ravandi F; Verstovsek S; Jorgensen JL; Bueso-Ramos C; Andreeff M; Pierce S; Garris R; Keating MJ; Cortes J; Kantarjian HM
    J Clin Oncol; 2010 Aug; 28(24):3880-9. PubMed ID: 20660823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.
    Thomas DA; Cortes J; O'Brien S; Pierce S; Faderl S; Albitar M; Hagemeister FB; Cabanillas FF; Murphy S; Keating MJ; Kantarjian H
    J Clin Oncol; 1999 Aug; 17(8):2461-70. PubMed ID: 10561310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.
    Evens AM; Carson KR; Kolesar J; Nabhan C; Helenowski I; Islam N; Jovanovic B; Barr PM; Caimi PF; Gregory SA; Gordon LI
    Ann Oncol; 2013 Dec; 24(12):3076-81. PubMed ID: 24146219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of treatment with Hyper-CVAD regimen in Chinese patients with acute lymphocytic leukemia.
    Xu W; Li JY; Qian SX; Wu HX; Lu H; Chen LJ; Zhang SJ; Lu RL; Sheng RL
    Leuk Res; 2008 Jun; 32(6):930-5. PubMed ID: 18061665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of modified Hyper-CVAD regimen on non-Hodgkin's lymphoma and safety evaluation].
    Shi W; Shi YK; He XH; Yang JL; Zhang CG; Zhou SY; Dong M; Liu P; Qin Y; Yang S; Gui L; Lv Z
    Ai Zheng; 2009 Oct; 28(10):1083-7. PubMed ID: 19799818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.